Hepatitis B: a new weapon against an old enemy - Nature Medicine

Norge Nyheter Nyheter

Hepatitis B: a new weapon against an old enemy - Nature Medicine
Norge Siste Nytt,Norge Overskrifter
  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 53%

In our recent News and Views, T. Jake Liang from NIDDKgov discusses new strategies based on nucleic acid technologies to treat chronic hepatitis B WorldHepatitisDay

Chronic infection with hepatitis B virus afflicts more than 250 million people worldwide.

Effective vaccines and treatments that potently suppress viral levels and reduce liver inflammation have been available for over 20 years, but infection with HBV continues to exact a heavy public-health toll. The goal of a ‘cure’ for chronic infection with HBV remains elusive. At present, nucleoside analogs and interferon-α are the only approved therapies, and they rarely cure the infection

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

NatureMedicine /  🏆 451. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

A blueprint for eliminating cholera by 2030 - Nature MedicineA blueprint for eliminating cholera by 2030 - Nature MedicineCholera is endemic in 47 countries, but deaths from this disease can be eliminated with a package of low-cost measures implemented by community healthcare workers.
Les mer »

Financing the health needs of Ukrainian refugees - Nature MedicineFinancing the health needs of Ukrainian refugees - Nature MedicineFinancing the health needs of Ukrainian refugees. Correspondence from Wu Zeng Georgetown.
Les mer »

Symptoms and risk factors for long COVID in non-hospitalized adults - Nature MedicineSymptoms and risk factors for long COVID in non-hospitalized adults - Nature MedicineA retrospective analysis of primary care records in the UK reveals individual symptoms associated with SARS-CoV-2 infections that persisted for 12 weeks or more post-infection, as well as risk factors associated with developing LongCOVID unibirmingham
Les mer »

Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial - Nature MedicineSafety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial - Nature MedicineA first-in-human study of an antisense oligonucleotide targeting hepatitis B virus RNA provides initial insights into this potential new therapeutic modality for individuals with chronic HBV infection ASO HKUniversity NMEDClinical WorldHepatitisDay
Les mer »

Global elimination of hepatitis C virus by 2030: why not? - Nature MedicineGlobal elimination of hepatitis C virus by 2030: why not? - Nature MedicineThe World Health Organization’s targets for eliminating hepatitis C virus by 2030 have been deemed ambitious by many. However, we believe they are achievable, provided they are supported by global commitment.
Les mer »

Genetic risk score enhances the risk prediction of severe obesity in adult survivors of childhood cancer - Nature MedicineGenetic risk score enhances the risk prediction of severe obesity in adult survivors of childhood cancer - Nature MedicineA report from large cohorts of adult survivors of childhood cancer demonstrates that polygenic scores improve the risk prediction of developing severe obesity, providing opportunities for surveillance and mitigation interventions YadavSapkota8 StJude
Les mer »



Render Time: 2025-04-04 23:13:12